Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 392

The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.

Programmed death ligand 1 signals in cancer cells

Open access
Kornepati, Anand V. R., Vadlamudi, Ratna K., Curiel, Tyler J.·2022·Nature Reviews Cancer

Abstract

The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to develop effective and revolutionary immunotherapies using antibodies blocking these cell-extrinsic interactions. The recent discovery of cancer cell-intrinsic PDL1 signals has broadened understanding of pathologic tumour PDL1 signal consequences that now includes control of tumour growth and survival pathways, stemness, immune effects, DNA damage responses and gene expression regulation. Many such effects are PD1-independent. These insights demonstrate that the prevailing cell-extrinsic PDL1 signalling paradigm is useful, but incomplete in important respects. This Perspective discusses historical and recent advances in understanding cancer cell-intrinsic PDL1 signals, mechanisms for signal controls and important immunopathologic consequences including resistance to cytotoxic agents, targeted small molecules and immunotherapies. Cancer cell-intrinsic PDL1 signals present novel drug discovery targets and also have potential as reliable treatment response biomarkers. Cancer cell-intrinsic PD1 signals and cell-intrinsic PDL1 signals in non-cancer cells are discussed briefly, as are PDL1 signals from soluble and vesicle-bound PDL1 and PDL1 isoforms. We conclude with suggestions for addressing the most pressing challenges and opportunities in this rapidly developing field. Cancer cell-intrinsic PDL1 signals present novel drug discovery targets and also have potential as treatment response biomarkers. This Perspective discusses our understanding of cancer cell-intrinsic PDL1 signals, mechanisms for signal controls and immunopathological consequences including resistance to cytotoxic agents, targeted small molecules and immunotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41568-021-00431-4

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 148 references

Cited by

See all 392

Metadata

Authors
Kornepati, A. V. R., Vadlamudi, R. K., & Curiel, T. J.
Venue
Nature Reviews Cancer
Published
2022-01-14
Volume
22
Issue
3
Pages
174-189
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W4206324389
Cited by
392
References
148
FWCI
15.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Programmed death ligand 1 signals in cancer cells. https://app.cochat.ai/papers/10.1038/s41568-021-00431-4
The paper
Kornepati, A. V. R., Vadlamudi, R. K., & Curiel, T. J. (2022). Programmed death ligand 1 signals in cancer cells. Nature Reviews Cancer. https://doi.org/10.1038/s41568-021-00431-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.